Skip to main content
    C

    Cytosorbents Crp (CTSO)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $4.85
    -0.02 (-0.41%)

    Market Cap: $15.35M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Cytosorbents Crp (CTSO) Financials: Revenue, Profit and Cash Flow

    Updated Aug 6, 2026. Financial statements from company filings, amounts in US dollars.

    Cytosorbents Crp reported revenue of $37.06M for the fiscal year ended Dec 31, 2025, up 4.1% from the year before. That year, net income was -$8.20M with a net margin of -22.1%, operating cash flow was -$12.38M and free cash flow was -$12.54M. The quarter ended Jun 30, 2026 had revenue of $9.63M and net income of -$4.42M.

    Revenue and Margins

    The operating margin was -39.8% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $9.53M, a compound annual rate of 16.3%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$37.06M+4.1%71.5%-39.8%-22.1%
    Dec 2024$35.59M+14.5%69.9%-46.2%-58.2%
    Dec 2023$31.08M-10.4%70.6%-102.8%-94.1%
    Dec 2022$34.69M-19.6%59.8%-90.9%-94.6%
    Dec 2021$43.17M+5.3%74.4%-52.7%-56.9%
    Dec 2020$41.00M+64.4%73.0%-25.3%-19.1%
    Dec 2019$24.95M+10.9%70.5%-76.0%-77.2%
    Dec 2018$22.50M+48.5%66.7%-69.3%-76.5%
    Dec 2017$15.15M+59.0%63.6%-65.0%-55.8%
    Dec 2016$9.53MN/A58.5%-120.6%-123.5%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Jun 2026, the company posted a net loss after a profit in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$37.06M$35.59M$31.08M$34.69M$43.17M$41.00M$24.95M$22.50M$15.15M$9.53M
    Cost of revenue$10.57M$10.71M$9.13M$13.96M$11.05M$11.05M$7.36M$7.49M$5.52M$3.95M
    Gross profit$26.49M$24.89M$21.95M$20.73M$32.12M$29.95M$17.59M$15.01M$9.63M$5.57M
    Research and development$5.08M$7.61M$15.59M$15.12M$16.38M$8.81M$12.09M$7.72M$3.22M$4.07M
    Operating income-$14.75M-$16.45M-$31.95M-$31.52M-$22.74M-$10.37M-$18.97M-$15.58M-$9.84M-$11.49M
    Net income-$8.20M-$20.72M-$29.25M-$32.81M-$24.56M-$7.84M-$19.27M-$17.21M-$8.46M-$11.76M
    EBITDA-$3.54MN/A-$27.88MN/AN/A-$6.78M-$18.63MN/A-$8.09MN/A
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Revenue$9.63M$8.86M$9.23M$9.48M$9.62M$8.73M$9.15M$8.61M$8.84M$8.99M$3.40M$8.81M
    Gross profit$7.05M$6.13M$6.80M$6.67M$6.81M$6.21M$6.25M$5.26M$6.50M$6.87M$4.87M$5.61M
    Operating income-$2.64M-$3.04M-$4.38M-$2.86M-$3.62M-$3.89M-$3.40M-$4.83M-$3.57M-$4.66M-$10.15M-$7.35M
    Net income-$4.42M-$5.13M-$5.50M-$3.17M$1.95M-$1.48M-$7.57M-$2.77M-$4.29M-$6.09M-$6.57M-$9.19M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $16.67M exceeded cash and equivalents by $10.42M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$44.18M$47.37M$52.96M$63.23M$89.52M$89.95M$27.38M$34.20M$24.10M$9.69M
    Current assets$20.63M$21.60M$25.40M$33.76M$64.30M$82.45M$20.90M$28.26M$20.74M$7.83M
    Cash and equivalents$6.25M$3.28M$14.13M$22.14M$52.14M$71.42M$12.23M$22.37M$17.32M$5.25M
    Total liabilities$38.28M$36.27M$29.48M$27.86M$26.94M$10.73M$23.96M$17.26M$13.84M$8.36M
    Short-term debt$0$452.69K$2.50M$0$570.57K$447.49K$1.67M$666.67K$4.00M$833.33K
    Long-term debt$16.67M$14.00M$2.54M$5.00M$0N/A$13.39M$9.27M$5.99M$4.08M
    Shareholder equity$5.90M$11.11M$23.48M$35.37M$62.58M$79.22M$3.42M$16.93M$10.26M$1.34M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$37.96M$40.56M$44.18M$45.75M$47.99M$50.78M$47.37M$47.80M$53.43M$47.07M$53.26M$47.58M
    Total liabilities$38.71M$38.37M$38.28M$36.73M$36.40M$36.24M$36.26M$34.80M$36.69M$28.14M$29.99M$29.06M
    Cash and equivalents$4.41M$4.81M$6.25M$7.54M$10.20M$11.59M$3.28M$5.69M$8.46M$8.61M$14.13M$8.36M
    Shareholder equity-$751.00K$2.19M$5.90M$9.02M$11.59M$14.54M$11.11M$13.00M$16.74M$18.93M$23.28M$18.51M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$12.38M-$14.43M-$21.66M-$28.23M-$14.01M-$5.61M-$16.76M-$10.84M-$6.46M-$6.73M
    Capital expenditures$164.00K$284.00K$538.12K$6.09M$3.64M$708.39K$698.16K$671.97K$990.67K$140.72K
    Free cash flow-$12.54M-$14.71M-$22.19M-$34.32M-$17.65M-$6.32M-$17.46M-$11.51M-$7.45M-$6.87M
    Dividends paidN/AN/AN/A$5.00MN/AN/AN/AN/A$335.73K$0
    Investing cash flow-$415.00K-$669.00K-$936.24K-$6.46M-$4.28M-$1.68M-$1.52M-$1.52M-$1.68M$1.60M
    Financing cash flow$9.31M$9.33M$14.47M$4.96M$715.20K$66.35M$8.18M$17.47M$20.12M$5.06M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow-$583.00K-$1.16M-$4.83M-$2.58M-$1.51M-$3.47M-$2.34M-$2.46M-$4.79M-$4.83M-$6.41M-$5.21M
    Capital expenditures$14.00K$11.00K$108.00K$17.00K$37.00K$2.00K$69.00K$152.00K$17.81K$45.19K$95.50K$142.40K
    Free cash flow-$597.00K-$1.17M-$4.93M-$2.59M-$1.55M-$3.47M-$2.41M-$2.62M-$4.81M-$4.87M-$6.50M-$5.35M
    Last 12 quarters

    Frequently Asked Questions About CTSO

    What is Cytosorbents Crp's annual revenue?

    Cytosorbents Crp reported revenue of $37.06M for the fiscal year ended Dec 31, 2025.

    How fast is Cytosorbents Crp's revenue growing?

    Revenue was up 4.1% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 2.2%.

    Is Cytosorbents Crp profitable?

    No. Cytosorbents Crp reported net income of -$8.20M for the fiscal year ended Dec 31, 2025, with a net margin of -22.1%.

    How much free cash flow does CTSO generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$12.38M minus capital expenditures of $164.00K produced free cash flow of -$12.54M.

    How much debt does Cytosorbents Crp have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $16.67M, short-term debt of $0 and cash and equivalents of $6.25M.